Effect of Single Dose Fluconazole 150mg on Lovastatin Levels
A single 150mg dose of fluconazole can significantly increase lovastatin levels and should be avoided due to the risk of rhabdomyolysis and other serious adverse effects.
Mechanism of Interaction
Fluconazole inhibits CYP3A4, the primary enzyme responsible for lovastatin metabolism. This interaction leads to:
- Increased plasma concentrations of both lovastatin and its active metabolite (lovastatin acid)
- Prolonged half-life of lovastatin in the bloodstream
- Increased risk of concentration-dependent adverse effects
Magnitude of Effect
While the research specifically examining a single 150mg dose of fluconazole with lovastatin is limited, similar azole antifungals have demonstrated dramatic effects:
- Itraconazole (another azole antifungal) increases lovastatin concentrations more than 20-fold 1
- Even at lower doses (100mg daily), itraconazole elevates lovastatin and lovastatin acid plasma concentrations approximately 15-fold 2
- A similar statin (simvastatin) combined with fluconazole has been documented to cause rhabdomyolysis 3
Clinical Implications
This drug interaction poses significant risks:
- Increased risk of myopathy and rhabdomyolysis
- Potential for liver toxicity
- Risk of acute kidney injury secondary to rhabdomyolysis
Management Recommendations
- Avoid concurrent use of fluconazole and lovastatin whenever possible
- If treatment for fungal infection is necessary:
- Consider alternative antifungal agents with less CYP3A4 inhibition
- Consider temporarily discontinuing lovastatin during fluconazole treatment
- If both medications are absolutely necessary, significantly reduce lovastatin dose and monitor closely
Monitoring
If concurrent use cannot be avoided:
- Monitor for symptoms of myopathy (muscle pain, weakness, tenderness)
- Check creatine kinase levels
- Monitor liver function tests
- Educate patient to report any muscle pain, weakness, or dark urine immediately
Alternative Approaches
- Alternative statins: Consider switching to fluvastatin, which is minimally affected by CYP3A4 inhibitors 2
- Alternative antifungals: For uncomplicated fungal infections, topical antifungal agents may be appropriate 4
Common Pitfalls
- Underestimating the significance of this interaction with just a single dose of fluconazole
- Failing to recognize early symptoms of myopathy
- Not considering the additive risk when other CYP3A4 inhibitors are used concurrently
This drug interaction represents a significant clinical concern even with a single dose of fluconazole, as the inhibition of CYP3A4 can persist beyond the immediate presence of fluconazole in the bloodstream.